Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus Of India, Teva Of Israel Settle Two Generics Disputes

This article was originally published in PharmAsia News

Executive Summary

India's ZydusCadila and Israel's Teva have reached a settlement of generics makers over a patent dispute involving the active pharmaceutical ingredients of multinational company antipsychotic drugs. Zydus and Teva had squabbled over competing generics to be marketed in the United States, but the settlement allows Zydus to sell its versions without facing a legal challenge by Teva. The API at issue is carvedilol, used in GlaxoSmithKline's Coreg, which lost its patent protection last year. Zydus had sued Teva over a generic of Johnson & Johnson's Risperdol (risperidone), accusing the Israeli company of antitrust and deceptive filings with the U.S. Patent and Trademark Office. (Click here for more

You may also be interested in...



Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

SC071959

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel